FY2025 EPS Estimates for BMRN Increased by Cantor Fitzgerald

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a report released on Tuesday, October 14th. Cantor Fitzgerald analyst O. Brayer now expects that the biotechnology company will post earnings of $4.02 per share for the year, up from their prior estimate of $3.78. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. Cantor Fitzgerald also issued estimates for BioMarin Pharmaceutical’s FY2026 earnings at $4.81 EPS.

Several other analysts also recently issued reports on BMRN. JPMorgan Chase & Co. upped their price objective on BioMarin Pharmaceutical from $116.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Morgan Stanley reduced their price objective on BioMarin Pharmaceutical from $97.00 to $96.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 22nd. Guggenheim upped their price objective on BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a “buy” rating in a research report on Wednesday, August 6th. Weiss Ratings restated a “sell (d+)” rating on shares of BioMarin Pharmaceutical in a research report on Wednesday, October 8th. Finally, Zacks Research downgraded BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Thirteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus price target of $93.26.

BioMarin Pharmaceutical Stock Down 0.3%

Shares of NASDAQ:BMRN opened at $52.95 on Thursday. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical has a 52-week low of $51.56 and a 52-week high of $73.51. The stock’s fifty day simple moving average is $55.74 and its 200-day simple moving average is $57.67. The company has a market capitalization of $10.17 billion, a P/E ratio of 15.71, a P/E/G ratio of 0.67 and a beta of 0.33.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in BMRN. Farther Finance Advisors LLC increased its stake in BioMarin Pharmaceutical by 95.9% in the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 211 shares during the last quarter. GAMMA Investing LLC increased its stake in BioMarin Pharmaceutical by 154.0% in the first quarter. GAMMA Investing LLC now owns 3,129 shares of the biotechnology company’s stock valued at $221,000 after purchasing an additional 1,897 shares during the last quarter. Fifth Third Bancorp increased its stake in BioMarin Pharmaceutical by 76.2% during the first quarter. Fifth Third Bancorp now owns 2,381 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 1,030 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in BioMarin Pharmaceutical by 92.2% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 44,584 shares of the biotechnology company’s stock worth $3,152,000 after acquiring an additional 21,383 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in BioMarin Pharmaceutical by 5.2% during the first quarter. Exchange Traded Concepts LLC now owns 19,796 shares of the biotechnology company’s stock worth $1,399,000 after acquiring an additional 979 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.